RecruitingInterventional · Not applicableNCT05230173 ↗Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RecruitingInterventional · Phase 3NCT06405087 ↗A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Subcutaneous in Pediatric Subjects With Ulcerative Colitis or Crohn's DiseaseAliza B SolomonPIInterventionDrug: Vedolizumab SC · Other: No InterventionDatesOct 2025 – Aug 2030 (est.)SponsorTakeda Development Center Americas, Inc.Ulcerative ColitisCrohn's Disease
Enrolling by invitationInterventional · Not applicableNCT06560021 ↗A Randomized Trial of the Utility of Random Biopsies in Patients With Inflammatory Bowel DiseaseDana Jeremy LukinPIInterventionOther: Biopsy strategyDatesJan 2025 – Dec 2028 (est.)SponsorUniversity of PennsylvaniaInflammatory Bowel DiseasesCrohn DiseaseUlcerative Colitis
RecruitingInterventional · Phase 2NCT07012395 ↗Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative ColitisDana Jeremy LukinPIInterventionDrug: SPY001 · Drug: SPY002 · Drug: SPY003 · Other: PlaceboDatesMay 2025 – Jun 2027 (est.)SponsorSpyre Therapeutics INCUlcerative ColitisInflammatory Bowel DiseasesColitis+1 more
CompletedInterventional · Not applicableNCT04672161 ↗Education Intervention on Vaccination Adherence Among IBD Patients at Weill Cornell Medical CenterDana Jeremy LukinPIInterventionOther: Vaccine EducationDatesFeb 2021 – Jun 2022SponsorWeill Medical College of Cornell UniversityCrohn Disease (CD)Ulcerative Colitis (UC)Indeterminate Colitis
CompletedInterventional · Phase 2NCT04996797 ↗A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy With PRA023 in Subjects With Moderately to Severely Active Ulcerative ColitisRandy LongmanPIInterventionDrug: Tulisokibart · Device: Companion Diagnostic (CDx) Testing · Other: PlaceboDatesJul 2021 – Jun 2023· Results postedSponsorPrometheus Biosciences, IncUlcerative Colitis
TerminatedInterventional · Phase 2NCT05370885 ↗Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients With Mild-to-Moderate Ulcerative ColitisDana Jeremy LukinPIInterventionBiological: VE202 · Drug: Vancomycin Oral Capsule · Other: VE202 Placebo · Other: Vancomycin PlaceboDatesMay 2023 – Aug 2025SponsorVedanta Biosciences, Inc.Ulcerative ColitisColitis, Ulcerative